Opiant Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Opiant Pharmaceuticals's earnings have been declining at an average annual rate of -22.2%, while the Pharmaceuticals industry saw earnings growing at 8.5% annually. Revenues have been growing at an average rate of 10.3% per year.
Key information
-22.2%
Earnings growth rate
-10.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 10.3% |
| Return on equity | -161.4% |
| Net Margin | -148.1% |
| Last Earnings Update | 30 Sep 2022 |
Recent past performance updates
Recent updates
Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Analysts Just Slashed This Year's Estimates
Aug 13
Opiant awarded additional $2.1M from BARDA for its nasal opioid overdose treatment
Aug 08Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Shares Could Be 47% Below Their Intrinsic Value Estimate
Aug 05Analysts Just Made A Major Revision To Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Revenue Forecasts
Mar 21Opiant Pharmaceuticals (NASDAQ:OPNT) Is Posting Healthy Earnings, But It Is Not All Good News
Nov 19These 4 Measures Indicate That Opiant Pharmaceuticals (NASDAQ:OPNT) Is Using Debt Reasonably Well
Nov 17Opiant Pharmaceuticals: Assessing Recent Insider Buying
Sep 19Party Time: Brokers Just Made Major Increases To Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Earnings Forecasts
Aug 07Increases to CEO Compensation Might Be Put On Hold For Now at Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT)
Jun 09The Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Yearly Results Are Out And Analysts Have Published New Forecasts
Mar 06News Flash: Analysts Just Made A Substantial Upgrade To Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Forecasts
Mar 05Opiant Pharmaceuticals'(NASDAQ:OPNT) Share Price Is Down 41% Over The Past Three Years.
Jan 27Opiant Pharma secures additional BARDA grant of $3.5M for OPNT003
Dec 14Opiant Pharmaceuticals receives $50M in convertible debt financing
Dec 10Revenue & Expenses BreakdownBeta
How Opiant Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 22 | 22 | -33 | 24 | 0 |
| 30 Jun 22 | 39 | -20 | 23 | 0 |
| 31 Mar 22 | 46 | -6 | 20 | 0 |
| 31 Dec 21 | 48 | 3 | 17 | 0 |
| 30 Sep 21 | 44 | 2 | 16 | 0 |
| 30 Jun 21 | 37 | -1 | 16 | 0 |
| 31 Mar 21 | 32 | -3 | 16 | 0 |
| 31 Dec 20 | 30 | -2 | 16 | 0 |
| 30 Sep 20 | 27 | 0 | 15 | 0 |
| 30 Jun 20 | 39 | 10 | 15 | 0 |
| 31 Mar 20 | 39 | 12 | 13 | 0 |
| 31 Dec 19 | 41 | 12 | 13 | 0 |
| 30 Sep 19 | 38 | 1 | 12 | 0 |
| 30 Jun 19 | 21 | -11 | 12 | 0 |
| 31 Mar 19 | 18 | -14 | 12 | 0 |
| 31 Dec 18 | 14 | -21 | 11 | 0 |
| 30 Sep 18 | 34 | -2 | 18 | 0 |
| 30 Jun 18 | 29 | -5 | 17 | 0 |
| 31 Mar 18 | 30 | -3 | 16 | 0 |
| 31 Dec 17 | 28 | 3 | 15 | 0 |
| 31 Oct 17 | 17 | 2 | 11 | 4 |
| 31 Jul 17 | 18 | 7 | 8 | 0 |
| 30 Apr 17 | 15 | 6 | 7 | 2 |
| 31 Jan 17 | 18 | 9 | 5 | 3 |
| 31 Oct 16 | 11 | 3 | 5 | 3 |
| 31 Jul 16 | 10 | -8 | 15 | 3 |
| 30 Apr 16 | 10 | -8 | 15 | 4 |
Quality Earnings: OPNT is currently unprofitable.
Growing Profit Margin: OPNT is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: OPNT is unprofitable, and losses have increased over the past 5 years at a rate of 22.2% per year.
Accelerating Growth: Unable to compare OPNT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: OPNT is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-17.3%).
Return on Equity
High ROE: OPNT has a negative Return on Equity (-161.39%), as it is currently unprofitable.